Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 6/20 | 0.54 |
| ▸ | RORA | P35398 | 6/20 | 0.49 |
| ▸ | RORC | P51449 | 6/20 | 0.49 |
| ▸ | RORB | Q92753 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227521 | 0.99 | KDM4E (0.56) | KDM4ERCE1PGRRORARORC | |
| SCHEMBL20227463 | 0.99 | KDM4E (0.58) | KDM4ERCE1PGRRORARORC | |
| SCHEMBL13762061 | 0.88 | TSPO (0.52) | KDM4ERCE1TSPONPY5RALDH1A1 | |
| SCHEMBL13762060 | 0.88 | TSPO (0.52) | KDM4ERCE1TSPONPY5RALDH1A1 | |
| SCHEMBL21450850 | 0.88 | NPY5R (0.54) | KDM4ERCE1MAPK14TSPONPY5R | |
| SCHEMBL20227623 | 0.87 | KDM4E (0.52) | KDM4ERCE1PGRMAPK14TSPO | |
| SCHEMBL13761791 | 0.85 | TSPO (0.56) | KDM4ERCE1TSPONPY5RALDH1A1 | |
| SCHEMBL13761788 | 0.85 | TSPO (0.56) | KDM4ERCE1TSPONPY5RALDH1A1 | |
| SCHEMBL13761793 | 0.85 | TSPO (0.56) | KDM4ERCE1TSPONPY5RALDH1A1 | |
| SCHEMBL13761830 | 0.85 | TSPO (0.56) | KDM4ERCE1TSPONPY5RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713319-B2 | Compounds having valerolactam structures | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713319-B2 | Compounds having valerolactam structures | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-20200031827-A1 | COMPOUNDS HAVING VALEROLACTAM STRUCTURES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713319-B2 | Compounds having valerolactam structures | ACE, CYP3A4, CYP2D6 | KDM4E 587/4885RCE1 407/4885PGR 818/4885 |
| US-20200031827-A1 | COMPOUNDS HAVING VALEROLACTAM STRUCTURES | ACE, CYP3A4, CYP2D6 | KDM4E 587/4885RCE1 407/4885PGR 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.